A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS 329993 in Subjects With Rheumatoid Arthritis.
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2016
At a glance
- Drugs ISIS CRPRx (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Proof of concept
- 10 Jun 2017 Biomarkers information updated
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History